Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data to Acquire Icoria in $12.5M Stock Deal

NEW YORK, Sept. 20 (GenomeWeb News) - Clinical Data plans to acquire Icoria in an all-stock transaction valued at approximately $12.5 million, the companies said today.

"Icoria's biomarker discovery platform is an excellent fit with our molecular diagnostics business model while their metabolomics and genomics capabilities complement that pharmacogenomics capabilities we will be gaining in our pending acquisition of Genaissance Pharmaceuticals," said Clinical Data's president and CEO Israel Stein in a company statement. Clinical Data said in June that it will acquire Genaissance.

Under the agreement, which still requires approval by Icoria's shareholders, Clinical Data will issue 0.0139 of its own shares for each share of Icoria common stock, representing a price of $.32 per Icoria share based on the closing price of Clinical's stock last Friday.

The acquisition is expected to close late this year or early in 2006. The aggregate purchase price could fluctuate, depending on Clinical Data's common stock price, but will in no case be less than $10 million or more than $12.5 million.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.